217 related articles for article (PubMed ID: 26215677)
21. USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor α.
Cao J; Wu D; Wu G; Wang Y; Ren T; Wang Y; Lv Y; Sun W; Wang J; Qian C; He L; Yang K; Li H; Gu H
Cell Death Dis; 2021 Jun; 12(6):619. PubMed ID: 34131114
[TBL] [Abstract][Full Text] [Related]
22. Heat shock factor 1 (HSF1) cooperates with estrogen receptor α (ERα) in the regulation of estrogen action in breast cancer cells.
Vydra N; Janus P; Kus P; Stokowy T; Mrowiec K; Toma-Jonik A; Krzywon A; Cortez AJ; Wojtas B; Gielniewski B; Jaksik R; Kimmel M; Widlak W
Elife; 2021 Nov; 10():. PubMed ID: 34783649
[TBL] [Abstract][Full Text] [Related]
23. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.
Goodman CR; Sato T; Peck AR; Girondo MA; Yang N; Liu C; Yanac AF; Kovatich AJ; Hooke JA; Shriver CD; Mitchell EP; Hyslop T; Rui H
Oncogene; 2016 Mar; 35(11):1373-85. PubMed ID: 26096934
[TBL] [Abstract][Full Text] [Related]
24. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
25. The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers.
Légaré S; Cavallone L; Mamo A; Chabot C; Sirois I; Magliocco A; Klimowicz A; Tonin PN; Buchanan M; Keilty D; Hassan S; Laperrière D; Mader S; Aleynikova O; Basik M
Cancer Res; 2015 Oct; 75(20):4351-63. PubMed ID: 26297734
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer.
Wang J; Shidfar A; Ivancic D; Ranjan M; Liu L; Choi MR; Parimi V; Gursel DB; Sullivan ME; Najor MS; Abukhdeir AM; Scholtens D; Khan SA
Int J Cancer; 2017 Jun; 140(11):2484-2497. PubMed ID: 28263391
[TBL] [Abstract][Full Text] [Related]
27. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
[No Abstract] [Full Text] [Related]
28. Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells.
Pescatori S; Leone S; Cipolletti M; Bartoloni S; di Masi A; Acconcia F
J Exp Clin Cancer Res; 2022 Apr; 41(1):141. PubMed ID: 35418303
[TBL] [Abstract][Full Text] [Related]
29. Amplification of WHSC1L1 regulates expression and estrogen-independent activation of ERα in SUM-44 breast cancer cells and is associated with ERα over-expression in breast cancer.
Irish JC; Mills JN; Turner-Ivey B; Wilson RC; Guest ST; Rutkovsky A; Dombkowski A; Kappler CS; Hardiman G; Ethier SP
Mol Oncol; 2016 Jun; 10(6):850-65. PubMed ID: 27005559
[TBL] [Abstract][Full Text] [Related]
30. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.
Arendt LM; Rugowski DE; Grafwallner-Huseth TA; Garcia-Barchino MJ; Rui H; Schuler LA
Breast Cancer Res; 2011 Jan; 13(1):R11. PubMed ID: 21276249
[TBL] [Abstract][Full Text] [Related]
31. Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13.
Bentin Toaldo C; Alexi X; Beelen K; Kok M; Hauptmann M; Jansen M; Berns E; Neefjes J; Linn S; Michalides R; Zwart W
BMC Cancer; 2015 Aug; 15():588. PubMed ID: 26272591
[TBL] [Abstract][Full Text] [Related]
32. Ring finger protein 6 promotes breast cancer cell proliferation by stabilizing estrogen receptor alpha.
Zeng Y; Xu X; Wang S; Zhang Z; Liu Y; Han K; Cao B; Mao X
Oncotarget; 2017 Mar; 8(12):20103-20112. PubMed ID: 28223545
[TBL] [Abstract][Full Text] [Related]
33. Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.
Tsuboi K; Kaneko Y; Nagatomo T; Fujii R; Hanamura T; Gohno T; Yamaguchi Y; Niwa T; Hayashi SI
J Steroid Biochem Mol Biol; 2017 Mar; 167():115-125. PubMed ID: 27888136
[TBL] [Abstract][Full Text] [Related]
34. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
35. RUNX1T1, a potential prognostic marker in breast cancer, is co-ordinately expressed with ERα, and regulated by estrogen receptor signalling in breast cancer cells.
Saikia S; Pal U; Kalita DJ; Rai AK; Sarma A; Kataki AC; Limaye AM
Mol Biol Rep; 2021 Jul; 48(7):5399-5409. PubMed ID: 34264479
[TBL] [Abstract][Full Text] [Related]
36. Tumour suppressor TET2 safeguards enhancers from aberrant DNA methylation and epigenetic reprogramming in ERα-positive breast cancer cells.
Lyu R; Zhu X; Shen Y; Xiong L; Liu L; Liu H; Wu F; Argueta C; Tan L
Epigenetics; 2022 Oct; 17(10):1180-1194. PubMed ID: 34689714
[TBL] [Abstract][Full Text] [Related]
37. VAV3 mediates resistance to breast cancer endocrine therapy.
Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
[TBL] [Abstract][Full Text] [Related]
38. ZBTB7A governs estrogen receptor alpha expression in breast cancer.
Molloy ME; Lewinska M; Williamson AK; Nguyen TT; Kuser-Abali G; Gong L; Yan J; Little JB; Pandolfi PP; Yuan ZM
J Mol Cell Biol; 2018 Aug; 10(4):273-284. PubMed ID: 30265334
[TBL] [Abstract][Full Text] [Related]
39. Novel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer.
Elbaz M; Ahirwar D; Ravi J; Nasser MW; Ganju RK
Oncotarget; 2017 May; 8(18):29668-29678. PubMed ID: 27213582
[TBL] [Abstract][Full Text] [Related]
40. Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis.
Padua MB; Bhat-Nakshatri P; Anjanappa M; Prasad MS; Hao Y; Rao X; Liu S; Wan J; Liu Y; McElyea K; Jacobsen M; Sandusky G; Althouse S; Perkins S; Nakshatri H
Breast Cancer Res; 2018 May; 20(1):35. PubMed ID: 29720215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
